X0202 SCHEDULE 13G 0001441252 XXXXXXXX LIVE Common Stock 04/14/2026 0001500198 NeuroOne Medical Technologies Corporation 64130M308 7599 Anagram Drive Eden Prairie MN 55344 Rule 13d-1(c) Brian Pratt b X1 0.00 627344.00 0.00 627344.00 627344.00 N 7.4 IN The amounts reported in boxes 6, 8, and 9 represent 627,344 shares of common stock, par value $0.001 per share ("Common Stock"), of NeuroOne Medical Technologies Corporation (the "Company"), held in a joint account with Brian Pratt's spouse. The percentage in box 11 is based on 8,420,999 shares of Common Stock outstanding following a 1-for-6 reverse stock split of 50,525,995 shares of Common Stock outstanding as of February 13, 2026, as reported in the Company's Quarterly Report on Form 10-Q filed on February 17, 2026. The reverse stock split was effective as of April 15, 2026, as reported in the Company's Current Report on Form 8-K filed on April 14, 2026. Barbara Pratt b X1 0.00 627344.00 0.00 627344.00 627344.00 N 7.4 IN The amounts reported in boxes 6, 8, and 9 represent 627,344 shares of common stock, par value $0.001 per share ("Common Stock"), of NeuroOne Medical Technologies Corporation (the "Company"), held in a joint account with Barbara Pratt's spouse. The percentage in box 11 is based on 8,420,999 shares of Common Stock outstanding following a 1-for-6 reverse stock split of 50,525,995 shares of Common Stock outstanding as of February 13, 2026, as reported in the Company's Quarterly Report on Form 10-Q filed on February 17, 2026. The reverse stock split was effective as of April 15, 2026, as reported in the Company's Current Report on Form 8-K filed on April 14, 2026. NeuroOne Medical Technologies Corporation 7599 Anagram Drive, Eden Prairie, MN 55344 Brian Pratt; and Barbara Pratt The address of the principal business office of each Reporting Person is 5950 Berkshire Lane, Ste. 800, Dallas, Texas 75225. Each Reporting Person is a citizen of the United States of America. Y The information set forth on the cover page of this Schedule 13G is incorporated herein by reference. The information set forth on the cover page of this Schedule 13G is incorporated herein by reference. The information set forth on the cover page of this Schedule 13G is incorporated herein by reference. The information set forth on the cover page of this Schedule 13G is incorporated herein by reference. The information set forth on the cover page of this Schedule 13G is incorporated herein by reference. The information set forth on the cover page of this Schedule 13G is incorporated herein by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Joint Filing Agreement, dated as of April 21, 2026, by and between the Reporting Persons, attached hereto. Brian Pratt /s/ Brian Pratt 04/21/2026 Barbara Pratt /s/ Barbara Pratt 04/21/2026